Title: Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric
neuroendocrine neoplasms
Version: 1 Date: 03 Jan 2021
Reviewer's report:
The present manus by Dou et al. presents miRNA202-3p as a novel possible marker for GNENs
type 1.
I suggest a major revision.
Minor comments:
Background: Well differentiated GNENs are divided in ECL-cell carcinoids (type 1-3) and non
ECL-cell carcinoids according to WHO 2010. The classification that the authors present is not
valid.
Results: “To investigate the characteristics of patients in more detail, gastroscopy and pathology
were performed after collecting blood samples.” The above phrase should be moved to material
and methods.
Results: “The ultrasonic gastroscopy” should be altered to “endoscopic ultrasound
investigation”.
At figure 2 it is shown that 5 patients did not have polyps but at Grading it is shown that 26
cases were of G1 and 1 of G2. At the cases without polyps from which areas were the biopsies
taken? What was the pathology? Furthermore, under the title abnormal proliferation of gastric
NE cells how the authors define tumor?
Discussion: “This leads to achlorhydria and corresponding symptoms such as bloating,
indigestion, and constipation”. These symptoms are not relevant to GNENs, the authors do not
present a reference either.
Major comments:
Discussion: “However, there was no significant stratified diagnostic value between serum
miRNA-202-3p levels in patients with different pathologies and different gastroscopic findings.”
I suggest that the authors will present at the results correlation between mi-RNA-202-3p and
size of largest polyp, number of polyps and grade OLGIM classification. Is mi-RNA-202-3p
more increased in patients with more advanced disease?
Gastrin levels should be also presented as hypergastrinemia is a cornerstone for the diagnosis
of type 1 ECLomas.
Title: Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric
neuroendocrine neoplasms
Version: 1 Date: 03 Jan 2021
Reviewer's report:
The present manus by Dou et al. presents miRNA202-3p as a novel possible marker for GNENs
type 1.
I suggest a major revision.
Minor comments:
Background: Well differentiated GNENs are divided in ECL-cell carcinoids (type 1-3) and non
ECL-cell carcinoids according to WHO 2010. The classification that the authors present is not
valid.
Results: “To investigate the characteristics of patients in more detail, gastroscopy and pathology
were performed after collecting blood samples.” The above phrase should be moved to material
and methods.
Results: “The ultrasonic gastroscopy” should be altered to “endoscopic ultrasound
investigation”.
At figure 2 it is shown that 5 patients did not have polyps but at Grading it is shown that 26
cases were of G1 and 1 of G2. At the cases without polyps from which areas were the biopsies
taken? What was the pathology? Furthermore, under the title abnormal proliferation of gastric
NE cells how the authors define tumor?
Discussion: “This leads to achlorhydria and corresponding symptoms such as bloating,
indigestion, and constipation”. These symptoms are not relevant to GNENs, the authors do not
present a reference either.
Major comments:
Discussion: “However, there was no significant stratified diagnostic value between serum
miRNA-202-3p levels in patients with different pathologies and different gastroscopic findings.”
I suggest that the authors will present at the results correlation between mi-RNA-202-3p and
size of largest polyp, number of polyps and grade OLGIM classification. Is mi-RNA-202-3p
more increased in patients with more advanced disease?
Gastrin levels should be also presented as hypergastrinemia is a cornerstone for the diagnosis
of type 1 ECLomas.
Please review this paper.
user
Title: Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric
neuroendocrine neoplasms
Version: 1 Date: 03 Jan 2021
Reviewer's report:
The present manus by Dou et al. presents miRNA202-3p as a novel possible marker for GNENs
type 1.
I suggest a major revision.
Minor comments:
Background: Well differentiated GNENs are divided in ECL-cell carcinoids (type 1-3) and non
ECL-cell carcinoids according to WHO 2010. The classification that the authors present is not
valid.
Results: “To investigate the characteristics of patients in more detail, gastroscopy and pathology
were performed after collecting blood samples.” The above phrase should be moved to material
and methods.
Results: “The ultrasonic gastroscopy” should be altered to “endoscopic ultrasound
investigation”.
At figure 2 it is shown that 5 patients did not have polyps but at Grading it is shown that 26
cases were of G1 and 1 of G2. At the cases without polyps from which areas were the biopsies
taken? What was the pathology? Furthermore, under the title abnormal proliferation of gastric
NE cells how the authors define tumor?
Discussion: “This leads to achlorhydria and corresponding symptoms such as bloating,
indigestion, and constipation”. These symptoms are not relevant to GNENs, the authors do not
present a reference either.
Major comments:
Discussion: “However, there was no significant stratified diagnostic value between serum
miRNA-202-3p levels in patients with different pathologies and different gastroscopic findings.”
I suggest that the authors will present at the results correlation between mi-RNA-202-3p and
size of largest polyp, number of polyps and grade OLGIM classification. Is mi-RNA-202-3p
more increased in patients with more advanced disease?
Gastrin levels should be also presented as hypergastrinemia is a cornerstone for the diagnosis
of type 1 ECLomas.
assistant